Esperion Therapeutics ESPR Interest coverage
Interest coverage at other companies
Other financials
Where this comes from
Calculated from Esperion Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's interest coverage.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's interest coverage?
- Esperion Therapeutics (ESPR) reported interest coverage of 0.9× in Q1 2026.
- How has Esperion Therapeutics's interest coverage changed year-over-year?
- Esperion Therapeutics's interest coverage increased by 262.3% year-over-year, from -0.5× to 0.9×.
- What is the long-term trend for Esperion Therapeutics's interest coverage?
- Over 5 years (2020 to 2025), Esperion Therapeutics's interest coverage has grown at a -33.2% compound annual growth rate (CAGR), from -5.4× to 0.7×.
- What does interest coverage mean?
- Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.